Physician profile
Christopher B Haas
NPI 1093786436
$4,038.05
in general payments reported to CMS, 2019-2025
17 companies · $856 in 2025
The $856 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $264 · 2020: $414 · 2021: $412 · 2022: $704 · 2023: $551 · 2024: $837 · 2025: $856.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,244.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,244.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,518.48 | 2020-2025 | Emblem Mri S-Icd, Lux-Dx Insertable Cardiac Monitor, Watchman Flx |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $478.44 | 2019-2025 | Lifevest |
| Amgen INC. | $197.75 | 2019-2025 | Krystexxa, Uplizna |
| Chiesi USA, INC. | $142.36 | 2019-2023 | Kengreal, Cleviprex |
| E.R. Squibb & Sons, L.L.C. | $133.17 | 2019-2025 | Eliquis, Camzyos |
| Abiomed | $102.31 | 2020 | |
| Lilly USA, LLC | $82.11 | 2020-2023 | Jardiance, Emgality |
| Novo Nordisk INC | $66.25 | 2019-2024 | Ozempic, Rybelsus |
| Cardiovascular Systems INC. | $65.74 | 2020-2023 | Diamondback Coronary |
| Abbvie INC. | $52.33 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $47.17 | 2020-2023 | Farxiga |
| Janssen Pharmaceuticals, INC | $38.21 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $32.28 | 2019 | |
| Novartis Pharmaceuticals Corporation | $32.22 | 2019-2024 | |
| Merit Medical Systems INC | $18.44 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $18.43 | 2019 | |
| Pfizer INC. | $12.36 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Haas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.